Company Overview of Cephalon, Inc.
Cephalon, Inc. engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. It offers NUVIGIL (armodafinil) tablets for improving wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea and shift work disorder, also known as shift work disorder and narcolepsy; TREANDA (bendamustine HCl) for injection for the treatment of patients with chronic lymphocytic leukemia; and AMRIX (Cyclobenzaprine Hydrochloride extended-release capsules), which is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions. The company also provi...
41 Moores Road
Frazer, PA 19355
Founded in 1987
Key Executives for Cephalon, Inc.
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Executive Vice President and President of Cephalon Europe Operations
Executive Vice President, Secretary and General Counsel
Chief Medical Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Compensation as of Fiscal Year 2016.
Cephalon, Inc. Key Developments
A.G. Schneiderman Announces $125 Million Settlement with Cephalon that Impeded Competition by Generic Prescription Makers
Aug 4 16
Attorney General, Eric T. Schneiderman has announced a $125 million, 48-state settlement with drug manufacturer Cephalon and affiliated companies (Cephalon), now part of Teva Pharmaceutical Industries. The settlement ends a multistate investigation into anticompetitive conduct by Cephalon to protect the profits it earned from having a patent-protected monopoly on the sale of its landmark drug, Provigil. Cephalon's conduct delayed generic versions of Provigil from entering the market for several years. As patent and regulatory barriers that prevented generic competition to Provigil neared expiration, an investigation found that Cephalon intentionally defrauded the Patent and Trademark Office to secure an additional patent, which a court subsequently deemed invalid and unenforceable. Before that court finding, Cephalon was able to delay generic competition for nearly six additional years by filing patent infringement lawsuits. Cephalon settled those lawsuits by paying competitors to delay sale of their generic versions of Provigil until at least April 2012. Because of that delayed entry, consumers, states, and others paid hundreds of millions more for Provigil than they would have had generic versions of the drug launched by early 2006, as expected. The settlement includes $35 million for distribution to consumers who bought Provigil. New York's total recovery will be $6 million in compensation to certain state entities and others who bought off of state contracts; an estimated $3.1 to $4.8 million for distribution to New York consumers who purchased Provigil; and $1.3 million for disgorgement and costs. This multistate settlement was facilitated by Federal Trade Commission litigation against Cephalon. In May 2015, the FTC settled its suit against Cephalon for injunctive relief and $1.2 billion, which was paid into an escrow account. The FTC settlement allowed for those escrow funds to be distributed for settlement of certain related cases and government investigations. The settlement is subject to court review, including providing consumers with notice and an opportunity to participate in, object to, or opt out of settlement. The states expect court review will be provided by Judge Mitchell Goldberg of the Eastern District of Pennsylvania, who is overseeing other litigation concerning Provigil against Cephalon and others.
Faruqi & Faruqi, LLP and Berger & Montague,P.C. Reach Whistleblower Lawsuit Settlement with AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc
Jul 7 15
Faruqi & Faruqi, LLP and co-counsel Berger & Montague,P.C. announced that they have reached a settlement in three separate but related whistleblower lawsuits alleging violations of the False Claims Act against AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc., for a total of $55.5 million. The cases were jointly prosecuted by Faruqi & Faruqi, LLP and Berger & Montague, P.C. on behalf of Relator Ronald J. Streck, who filed this action in 2008. Under the terms of the settlement, AstraZeneca will pay $46.5 million, Cephalon will pay $7.5 million, and Biogen will pay $1.5 million. Claims against a fourth drug manufacturer, Genzyme Corporation, are still being litigated. The case, pending in federal court in the Eastern District of Pennsylvania, is captioned United States ex rel. Ronald Streck versus Allergan, et al., Case No. 08-cv-5135. The lawsuit, filed on behalf of the United States under the False Claims Act (FCA) and State False Claims Acts alleges that a number of pharmaceutical manufacturers, including AstraZeneca, Cephalon and Biogen, fraudulently underpaid mandatory rebates to state Medicaid programs. Streck's lead attorney, T. Talyana Bromberg of Faruqi & Faruqi, LLP, stated: "When pharmaceutical companies manipulate prices in order to underpay Medicaid, every taxpayer suffers.
FTC Reaches Settlement with Cephalon Resolving the Commission's Antitrust Suit
May 28 15
The Federal Trade Commission has reached a settlement resolving the Commission's antitrust suit charging Cephalon, Inc. with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct. Some of these purchasers have settled related litigation and payments made by Teva in those or other actions can be credited against the FTC fund according to the terms of the stipulated order for equitable monetary relief. Any remaining funds will be paid to the U.S. Treasury. As part of the settlement, Teva also has agreed to a prohibition on the type of anticompetitive patent settlements that Cephalon used to artificially inflate the price of Provigil.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|